Every material Form 8-K KIORA PHARMACEUTICALS INC has filed with the SEC since August 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical on October 23, 2026, for the late-stage calpain inhibitor KIO-401, covering territories outside Asia. The deal calls for a $3.5 million upfront payment, a low-teen-million-dollar payment on technology transfer, and up to $168.5 million in milestones, and the company says it is evaluating financing to fund development. For shareholders, the filing adds near-term cash obligations and funding uncertainty, and it reports no revenue or earnings figures.
Upfront payment of $3.5 million to Senju, with a further low-teen-million-dollar payment upon technology transfer, a portion of which may be credited against future milestones.
Up to $168.5 million in additional regulatory and commercial milestone payments, plus single-digit royalties on net sales in the licensed territory.
Kiora discontinued research and development of KIO-104 and is evaluating financing alternatives to fund KIO-401 development.
Target initiation of the multinational Phase 3 CRAO trial is 2027, subject to funding and regulatory alignment.
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane previously served as Chief Scientific Officer at Ora, Inc., an ophthalmology-focused clinical research organization, and his role will cover clinical development for the current pipeline, including KIO-301 for retinitis pigmentosa.
Appointment effective September 8, 2026, under an offer letter dated June 22, 2026
Compensation includes a $350,000 annual base salary, a $75,000 sign-on bonus, and a performance bonus with a target of up to 35% of base salary
Option to purchase up to 55,000 shares, subject to Compensation Committee approval, with one-third vesting after one year and the rest in monthly installments over two years
Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation (CKD) an exclusive license to develop and commercialize KIO-301 in South Korea for retinitis pigmentosa and other ophthalmology uses, under an agreement effective August 20, 2026. Kiora will receive a $1.0 million upfront payment, plus eligible milestone payments and double-digit royalties on South Korean net sales, and says the deal completes its global partner network for the product.
CKD pays a $1.0 million upfront payment to Kiora under the Exclusive License and Development Agreement.
Kiora is eligible for clinical, regulatory and sales milestone payments and double-digit royalties on net sales of KIO-301 in South Korea.
CKD will handle development and commercialization in South Korea; Kiora expects its partners Laboratoires Théa, Senju Pharmaceutical and CKD to run a single global Phase 3 trial.
The agreement was announced in a press release dated August 19, 2026, and either party may terminate it upon certain customary events.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KIORA PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →